Continuing to work while receiving cancer treatment: A financial or a symbolic issue?

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6603-6603 ◽  
Author(s):  
Gerard Ganem ◽  
Herve L. Naman ◽  
Nadine Dohollou ◽  
Thomas Facchini ◽  
Yvan Coscas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Care Center ◽  
Median Number ◽  
New Drugs ◽  
Health Care Center ◽  
Financial Gain ◽  
After Cancer ◽  
Cure Rates ◽  
Do So

6603 Background: As improved cure rates lead to longer life expectancy, occupational concerns during and after cancer treatment become important. The advent of new drugs with fewer side effects will increase the profile of this issue. We carried out a field survey to explore the question. Methods: We questioned 97 oncologists, and a subgroup of 216 patients treated for breast cancer who were working at the time of diagnosis and who wanted to continue to do so during at least part of the treatment period. Results: Data Collected from Patients: In total, 208 patients (96%) were satisfied or very satisfied with their jobs. Only 68 (31%) were able to achieve the goal of working without interruption while being treated (physicians estimated that figure at only 11%). For the remaining women, who did stop working (69%), the median number of days off work was 59. Data Collected from Physicians: A total of 87 physicians (89%) stated that having information regarding working conditions is very important when counseling patients about whether they could continue to work. Comparison of the answers given by patients and physicians: 36% of physicians thought that the initiative in addressing the work/job issue was taken primarily by themselves, while 53% felt it came from the patient. The patient perspective was different: 61% of patients thought they took the initiative themselves and only 13% of them thought the physician took the lead. The main reason behind the desire to continue working is thought by 56% of physicians to be “Financial gain”; while for patients it is “To feel the same” (42%). A total of 90 (92%) physicians feared that those patients continuing to work would face at least one type of medical difficulty; only 143 (66%) patients shared this fear. Lastly, although 94% of the physicians have access to psychological or psychiatric support workers at the health care center, only 62% have access to a social worker. Conclusions: Of the patients who really wanted to work while being treated for breast cancer, only 31% could achieve that goal without any interruption. There is also a difference of perception regarding patient motivation, with physicians believing that the reasons are mainly financial while the patients see it as more of a symbolic issue.

Design of novel multi filter union feature selection framework for breast cancer dataset

2021 ◽  
pp. 1063293X2110160
Author(s):  
Dinesh Morkonda Gunasekaran ◽  
Prabha Dhandayudam
Keyword(s):  
Breast Cancer ◽  
Feature Selection ◽  
Care Center ◽  
Feature Selection Method ◽  
Selection Method ◽  
Cancer Center ◽  
Breast Cancer Dataset ◽  
Data Set ◽  
Health Care Center ◽  
Cancer Data

Nowadays women are commonly diagnosed with breast cancer. Feature based Selection method plays an important step while constructing a classification based framework. We have proposed Multi filter union (MFU) feature selection method for breast cancer data set. The feature selection process based on random forest algorithm and Logistic regression (LG) algorithm based union model is used for selecting important features in the dataset. The performance of the data analysis is evaluated using optimal features subset from selected dataset. The experiments are computed with data set of Wisconsin diagnostic breast cancer center and next the real data set from women health care center. The result of the proposed approach shows high performance and efficient when comparing with existing feature selection algorithms.

scholarly journals From Provision of Information, Through Activation, to Changing the Social World. The Amazonki Associations as a Source of Comprehensive Support for Women with Breast Cancer

2019 ◽  
Vol 9 (2) ◽  
pp. 56-72
Author(s):  
Edyta Zierkiewicz
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Social World ◽  
Breast Cancer Treatment ◽  
Women Patients ◽  
Mutual Help ◽  
The Social ◽  
After Cancer ◽  
Social Units

This work presents the phenomenon of mutual help and social support in a group of patients with breast cancer, against the background of transformations of the whole Amazonki (Amazons) movement. Social organizations embracing women after breast cancer treatment have been operating in Poland for over 30 years. In that time, they have proven their usefulness and importance. Since the beginning of their existence, the Amazons clubs were oriented to providing support, widely understood, to women patients in oncological wards and club members; they have been successful in that area so far. What is important is the fact that individual clubs of women after cancer treatment are not separate social units, but form a federation which, since the early 1990s, has been directing the process of rationalizing their operations. This work describes that process in general and presents the stage at which the Amazons movement is at present. What is interesting, the stagnation which has overcome the whole movement seems to have little or no effect at all on the functioning of separate associations, which pursue their statutory goal to support sick women in recovery and improve their quality of life.

scholarly journals Therapeutical evaluation of different dose regimens of praziquantel in schistosomiasis mansoni, based on the quantitative oogram technique

1987 ◽  
Vol 29 (5) ◽  
pp. 295-304 ◽  
Author(s):  
Aloísio Sales da Cunha ◽  
J. Romeu Cançado ◽  
Getúlio Leonel de Rezende
Keyword(s):  
Total Dose ◽  
False Negative ◽  
Rectal Mucosa ◽  
Median Number ◽  
New Drugs ◽  
Negative Results ◽  
Schistosomiasis Mansoni ◽  
Negative Findings ◽  
The Difference ◽  
Cure Rates

A clinical trial involving 80 patients of both sexes, from ages 15 to 55, with chronic intestinal or hepatointestinal schistosomiasis mansoni, was carried out to evaluate the therapeutical efficacy of different dose regimens of praziquantel. The patients were randomly allocated into four groups with an equal number of cases and were then treated with one of the following dosages: 60 mg/kg for 1 day; 60 mg/kg daily for 2 days; 60 mg/kg daily for 3 days; and 30 mg/kg daily for 6 days. The assessment of parasitological cure was based on the quantitative oogram technique through rectal mucosa biopsies which were undertaken prior to, as well as, 1,2,4 and 6 months post-treatment. Concurrently, stool examinations according to the qualitative Hoffman, Pons & Janer (HPJ) and the quantitative Kato-Katz (K-K) methods were also performed. The best tolerability was observed with 30 mg/kg daily for 6 days whereas the highest incidence of side-effects (mainly dizziness and nausea) was found with 60 mg/kg daily for 3 days. No serious adverse drug reaction has occurred. The achieved cure rates were: 25% with 60 mg/kg for 1 day; 60% with 60 mg/kg daily for 2 days; 89.5% with 60 mg/kg daily for 3 days; and 90% with 30 mg/kg daily for 6 days. At the same time there has been a downfall of 64%, 73%, 87% and 84% respectively, in the median number of viable S. mansoni ova per gram of tissue. Thus, a very clear direct correlation between dose and effect could be seen. The corresponding cure rates according to stool examinations by HPJ were 39%, 80%, 100% and 95%; by K-K 89%, 100%, 100% and 100%. This discrepancy in results amongst the three parasitological methods is certainly due to their unequal accuracy. In fact, when the number of viable eggs per gram of tissue fell below 5,000 the difference in the percentage of false negative findings between HPJ (28%) and K-K (80%) became significative. When this number dropped to less than 2,000 the percentage of false negative results obtained with HPJ (49%) turned significant in relation to the oogram as well. In conclusion, it has been proven that praziquantel is a highly efficacious agent against S. mansoni infections. If administered at a total dose of 180 mg/kg divided into either 3 or 6 days, it yields a 90% cure rate. Possibly, one could reach 100% by increasing the total dose to 240 mg/kg. Furthermore, it was confirmed that the quantitative oogram technique is the most reliable parasitological method when evaluating the efficacy of new drugs in schistosomiasis mansoni.

Crowdsourcing the collateral damage from breast cancer treatment.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 110-110
Author(s):  
Susan M. Love ◽  
Amaka Obidegwu ◽  
Christine A Fischetti
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Questionnaire Development ◽  
Breast Cancer Treatment ◽  
Medical Community ◽  
Collateral Damage ◽  
Advocacy Organizations ◽  
Memory Problems ◽  
After Cancer ◽  
Tract Infections

110 Background: Survivorship research focuses on quality of life after cancer treatment, but is usually initiated by providers and lacks the voice of the patient. In an effort to explore the patient perspective, we convened a collaboration of advocacy groups to “crowdsource” women’s questions regarding collateral damage from breast cancer treatment. These concerns will be incorporated into the Health of Women [HOW] Study, an ongoing, online cohort study open to anyone aged 18 or older. Methods: Emails to current HOW participants were sent out July 2013 to solicit questions. In October 2013, a new webpage was designed to collect responses; we then partnered with other advocacy organizations and began collecting responses, which were then categorized to guide questionnaire development. Results: Sixteen advocacy organizations came together to support this project. Emails to current HOW participants resulted in 1,191 responses. The website landing page resulted in 5,099 responses. Overall, 16.8% of respondents complained of fatigue, 16.3% of memory problems, 15.7% of anxiety and/or depression, and 14.0% of numbness/neuropathy. Other less frequently reported problems included problems with nail growth, vision, hearing, urinary tract infections, and allergy-like symptoms. Conclusions: We received an overwhelming number of responses about collateral damage. Many of the issues are known side effects, while others are less commonly reported. We will next compare responses to previously validated questionnaires, develop a comprehensive collateral damage questionnaire for inclusion in the HOW Study, and generate a report for publication to be distributed to participants and the medical community.

scholarly journals Research Progress of Anti-breast Cancer Peptides

2019 ◽  
Vol 4 (08) ◽  
Author(s):  
Zhi-Gang Sun ◽  
Zhi-Na Li ◽  
Liang-Hui Zhao ◽  
Jin-Mai Zhang
Keyword(s):  
Breast Cancer ◽  
Drug Resistance ◽  
Cancer Treatment ◽  
Malignant Tumor ◽  
Breast Cancer Treatment ◽  
New Drugs ◽  
Research Progress ◽  
Epithelial Tissue ◽  
Anti Cancer

Breast cancer is a malignant tumor that occurs in the epithelial tissue of the breast, mostly in female. At present, drug resistance has emerged in the treatment of breast cancer. Therefore, the discovery of new drugs for breast cancer is particularly important. Some peptides have been found to have anti-cancer effects. This article reviews the recent discoveries of anti-breast cancer peptides, hoping to provide some help for the development of breast cancer treatment.

Sign in / Sign up

Export Citation Format

Share Document